UBS Group
PLRX icon

UBS Group’s Pliant Therapeutics PLRX Stock Holding History

UBS Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$652K Sell
571,760
-486,194
-46% -$592K ﹤0.01% 6069
2026
Q1 		$1.33M Sell
1,057,954
-4,661
-0.4% -$5.88K ﹤0.01% 5324
2025
Q4 		$1.3M Sell
1,062,615
-259,402
-20% -$390K ﹤0.01% 5360
2025
Q3 		$1.96M Sell
1,322,017
-1,324,539
-50% -$2.02M ﹤0.01% 4972
2025
Q2 		$3.07M Buy
2,646,556
+1,010
+0% +$1.43K ﹤0.01% 4369
2025
Q1 		$3.57M Buy
2,645,546
+2,017,265
+321% +$12.2M ﹤0.01% 4139
2024
Q4 		$8.27M Buy
628,281
+397,973
+173% +$5.43M ﹤0.01% 3271
2024
Q3 		$2.58M Buy
230,308
+78,106
+51% +$977K ﹤0.01% 3747
2024
Q2 		$1.64M Sell
152,202
-212,862
-58% -$2.74M ﹤0.01% 3974
2024
Q1 		$5.44M Buy
365,064
+22,891
+7% +$378K ﹤0.01% 2886
2023
Q4 		$6.2M Buy
342,173
+71,369
+26% +$1.09M ﹤0.01% 2543
2023
Q3 		$4.7M Buy
270,804
+267,780
+8,855% +$4.64M ﹤0.01% 2634
2023
Q2 		$54.8K Sell
3,024
-11,536
-79% -$273K ﹤0.01% 6417
2023
Q1 		$387K Buy
14,560
+9,165
+170% +$261K ﹤0.01% 4891
2022
Q4 		$104K Sell
5,395
-1,205
-18% -$25.2K ﹤0.01% 6057
2022
Q3 		$138K Buy
6,600
+3,063
+87% +$58.6K ﹤0.01% 5425
2022
Q2 		$28K Buy
3,537
+550
+18% +$3.52K ﹤0.01% 6474
2022
Q1 		$21K Sell
2,987
-7,334
-71% -$74.8K ﹤0.01% 7398
2021
Q4 		$140K Buy
10,321
+8,391
+435% +$133K ﹤0.01% 5986
2021
Q3 		$32K Buy
1,930
+533
+38% +$11.3K ﹤0.01% 6694
2021
Q2 		$41K Buy
1,397
+501
+56% +$15.6K ﹤0.01% 6615
2021
Q1 		$35K Sell
896
-483
-35% -$15.7K ﹤0.01% 6882
2020
Q4 		$32K Sell
1,379
-1,131
-45% -$28.4K ﹤0.01% 6579
2020
Q3 		$57K Buy
+2,510
New +$62.7K ﹤0.01% 5550

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

UBS Group's PLRX Position: Q2 2026 in Review

UBS Group reduced its Pliant Therapeutics (PLRX) stake by 46% in Q2 2026, selling an estimated $592K and leaving 571,760 shares worth $652K. The position accounts for ﹤0.01% of the portfolio, ranked #6069.

UBS Group first reported a position in PLRX in Q3 2020 and has held it in 24 quarters since. The position peaked at $8.27M in Q4 2024. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • UBS Group held 571,760 shares of Pliant Therapeutics worth $652K as of Q2 2026.
  • UBS Group sold 486,194 Pliant Therapeutics shares in Q2 2026, an estimated $592K.
  • Pliant Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6069 holding.
  • UBS Group first reported a position in Pliant Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • UBS Group's Pliant Therapeutics position peaked at $8.27M in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.